-64%

est. 2Y upside i

HealthcareSeries A

Blood Test for Early Detection of Ovarian Cancer

Rank

#873

Sector

Biotechnology, Diagnostics, Women's Health

Est. Liquidity

~4Y

Data Quality

Data: Medium

AOA Dx presents a moderate upside opportunity for a job seeker, driven by its innovative multi-omics platform for early ovarian cancer detection in a large unmet market.

Last updated: March 10, 2026

Bull (30%)+350%

AOA Dx successfully completes clinical trials for AKRIVIS GD™, secures expedited FDA and European regulatory approvals, and achieves rapid market adoption due to its high accuracy and unmet need. This leads to early commercial traction, expansion into additional cancer indications, and a strategic acquisition by a major diagnostic or pharmaceutical company at a valuation of $380M+.

Base (30%)+75%

AOA Dx navigates the regulatory process successfully, albeit with some delays, and launches AKRIVIS GD™ for ovarian cancer. It gains moderate market penetration, establishing itself as a key player in early ovarian cancer detection. The company continues to raise additional capital, and achieves an exit (IPO or acquisition) at a valuation of approximately $150M.

Bear (40%)-85%

AOA Dx faces significant challenges in clinical trials, experiences substantial regulatory delays, or encounters stronger-than-anticipated competition from incumbents or other emerging technologies. This results in a down round or failure to secure sufficient additional funding, leading to a significantly reduced valuation of $12M-$20M, wiping out most common stock value due to liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

29%

Investors hold $24M in liquidation preferences. In an exit at the current $85M valuation, common shareholders would receive $61M. If the company exits at or below $24M, common shareholders would receive nothing.

Dilution Risk

high

As a clinical-stage biotech with high capital intensity, AOA Dx will require multiple additional funding rounds to complete trials and achieve commercialization, leading to significant future dilution for existing equity holders.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for AOA Dx equity, typical for a Series A stage private company.

View all 4 open roles at AOA Dx →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on AOA Dx's data — designed to show you've done your homework.

  • 1

    “Given the ongoing OVERT clinical trial and the need for FDA approval, what are the key milestones and timelines the company is focused on over the next 12-24 months to de-risk the regulatory pathway and prepare for commercialization?”

  • 2

    “AOA Dx's technology shows high accuracy compared to traditional biomarkers. How is the company planning to differentiate and compete against larger diagnostic players like Labcorp (an investor) or Quest Diagnostics, especially regarding market access, reimbursement, and physician adoption?”

  • 3

    “With a Series A in late 2023 and a recent filing for additional funding, what is the company's long-term funding strategy, and how does the leadership team envision a liquidity event for employees, considering the preference stack and potential for future dilution?”

Community

Valuation Sentiment

Our model estimates -64% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.